Guangzhou Baiyunshan Pharmaceutical Holdings Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Hong Li
Chief executive officer
CN¥1.5m
Total compensation
| CEO salary percentage | 30.6% |
| CEO tenure | 6.8yrs |
| CEO ownership | n/a |
| Management average tenure | 6.9yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | n/a | n/a | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥460k | CN¥4b |
| Sep 30 2022 | n/a | n/a | CN¥4b |
| Jun 30 2022 | n/a | n/a | CN¥4b |
| Mar 31 2022 | n/a | n/a | CN¥4b |
| Dec 31 2021 | CN¥2m | CN¥456k | CN¥4b |
| Sep 30 2021 | n/a | n/a | CN¥4b |
| Jun 30 2021 | n/a | n/a | CN¥4b |
| Mar 31 2021 | n/a | n/a | CN¥3b |
| Dec 31 2020 | CN¥1m | CN¥442k | CN¥3b |
| Sep 30 2020 | n/a | n/a | CN¥3b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥3b |
| Dec 31 2019 | CN¥1m | CN¥428k | CN¥3b |
| Sep 30 2019 | n/a | n/a | CN¥3b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥4b |
| Dec 31 2018 | CN¥1m | CN¥382k | CN¥3b |
Compensation vs Market: Hong's total compensation ($USD207.25K) is below average for companies of similar size in the Hong Kong market ($USD924.09K).
Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.
CEO
Hong Li (56 yo)
6.8yrs
Tenure
CN¥1,501,836
Compensation
Mr. Hong Li has been General Manager at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited since June 23, 2017 and serves as its Executive Director since June 22, 2018. Mr. Li started his career...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.8yrs | no data | no data | |
| GM & Executive Director | 6.8yrs | CN¥1.50m | no data | |
| Executive Vice Chairman | 11.6yrs | no data | no data | |
| Executive Vice Chairman | 4.3yrs | no data | no data | |
| Deputy GM & Executive Director | 9.3yrs | CN¥380.31k | no data | |
| Executive Director | no data | no data | no data | |
| Executive Director | 8.3yrs | CN¥300.62k | no data | |
| Deputy GM & Director of Business Administration Department | 4.8yrs | CN¥1.35m | no data | |
| Secretary | 7yrs | CN¥1.18m | no data |
6.9yrs
Average Tenure
56yo
Average Age
Experienced Management: 874's management team is seasoned and experienced (6.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.8yrs | no data | no data | |
| GM & Executive Director | 5.8yrs | CN¥1.50m | no data | |
| Executive Vice Chairman | 11.6yrs | no data | no data | |
| Executive Vice Chairman | 4.3yrs | no data | no data | |
| Deputy GM & Executive Director | 13.8yrs | CN¥380.31k | no data | |
| Executive Director | 10.3yrs | no data | no data | |
| Executive Director | 4.8yrs | CN¥300.62k | no data | |
| Independent Non-Executive Director | less than a year | CN¥50.00k | no data | |
| Chairman of the Supervisory Board | 4.6yrs | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | CN¥120.00k | no data | |
| Independent Non-Executive Director | 3.8yrs | CN¥120.00k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
4.7yrs
Average Tenure
57yo
Average Age
Experienced Board: 874's board of directors are considered experienced (4.7 years average tenure).